Epidemiological associations between iron and cardiovascular disease and diabetes

Frontiers in Pharmacology

Volumn 5 MAY, Issue , 2014, Pages

  Basuli, Debargha ^a   Stevens, Richard G ^a   Torti, Frank M ^a   Torti, Suzy V ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Epidemiologic studies; Iron; Metabolic syndrome

Indexed keywords

DEFEROXAMINE; FERRITIN; FREE RADICAL; HFE PROTEIN; INSULIN; IRON; IRON CHELATING AGENT; TRANSFERRIN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FERRITIN BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HEMOCHROMATOSIS; HUMAN; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; IRON ABSORPTION; IRON BALANCE; IRON INTAKE; IRON METABOLISM; IRON METABOLISM DISORDER; IRON OVERLOAD; IRON STORAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL STATUS; PHLEBOTOMY; REVIEW; RISK FACTOR;

EID: 84904696084     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00117     Document Type: Review

References (117)

1. Andrews, N. C. (1999). Disorders of iron metabolism. N. Engl. J. Med. 341, 1986-1995. doi: 10.1056/NEJM199912233412607.
2. Angulo, P. (2002). Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-1231. doi: 10.1056/NEJMra011775.
3. Baer, D. M., Tekawa, I. S., and Hurley, L. B. (1994). Iron stores are not associated with acute myocardial infarction. Circulation 89, 2915-2918. doi: 10.1161/01.CIR.89.6.2915.
4. Bao, W., Rong, Y., Rong, S., and Liu, L. (2012). Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis. BMC Med. 10:119. doi: 10.1186/1741-7015-10-119.
5. Barisani, D., Pelucchi, S., Mariani, R., Galimberti, S., Trombini, P., Fumagalli, D., et al. (2008). Hepcidin and iron-related gene expression in subjects with dysmetabolic hepatic iron overload. J. Hepatol. 49, 123-133. doi: 10.1016/j.jhep.2008.03.011.
6. Bekri, S., Gual, P., Anty, R., Luciani, N., Dahman, M., Ramesh, B., et al. (2006). Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131, 788-796. doi: 10.1053/j.gastro.2006.07.007.
7. Benson, K., and Hartz, A. J. (2000). A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med. 342, 1878-1886. doi: 10.1056/NEJM200006223422506.
8. Berliner, J. A., and Heinecke, J. W. (1996). The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20, 707-727. doi: 10.1016/0891-5849(95)02173-6.
9. Bo, S., Menato, G., Villois, P., Gambino, R., Cassader, M., Cotrino, I., et al. (2009). Iron supplementation and gestational diabetes in midpregnancy. Am. J. Obstet. Gynecol. 201, 158.e1-158.e6. doi: 10.1016/j.ajog.2009.04.049.
10. Bottiger, L. E., and Carlson, L. A. (1982). Risk factors for death for males and females. A study of the death pattern in the Stockholm prospective study. Acta Med. Scand. 211, 437-442. doi: 10.1111/j.0954-6820.1982.tb01978.x.
11. Bozzini, C., Girelli, D., Olivieri, O., Martinelli, N., Bassi, A., De Matteis, G., et al. (2005). Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 28, 2061-2063. doi: 10.2337/diacare.28.8.2061.
12. Castellanos, M., Puig, N., Carbonell, T., Castillo, J., Martinez, J., Rama, R., et al. (2002). Iron intake increases infarct volume after permanent middle cerebral artery occlusion in rats. Brain Res. 952, 1-6. doi: 10.1016/S0006-8993(02)03179-7.
13. Chan, K. K., Chan, B. C., Lam, K. F., Tam, S., and Lao, T. T. (2009). Iron supplement in pregnancy and development of gestational diabetes - a randomised placebo-controlled trial. BJOG 116, 789-797; discussion 797-788. doi: 10.1111/j.1471-0528.2008.02014.x.
14. Choi, K. M., Lee, K. W., Kim, H. Y., Seo, J. A., Kim, S. G., Kim, N. H., et al. (2005). Association among serum ferritin, alanine aminotransferase levels, and metabolic syndrome in Korean postmenopausal women. Metabolism 54, 1510-1514. doi: 10.1016/j.metabol.2005.05.018.
15. Concato, J., Shah, N., and Horwitz, R. I. (2000). Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342, 1887-1892. doi: 10.1056/NEJM200006223422507.
16. Cook, J. D., Lipschitz, D. A., Miles, L. E., and Finch, C. A. (1974). Serum ferritin as a measure of iron stores in normal subjects. Am. J. Clin. Nutr. 27, 681-687.
17. Cooksey, R. C., Jouihan, H. A., Ajioka, R. S., Hazel, M. W., Jones, D. L., Kushner, J. P., et al. (2004). Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology 145, 5305-5312. doi: 10.1210/en.2004-0392.
18. Cullen, K. J., Stenhouse, N. S., and Wearne, K. L. (1981). Raised haemoglobin and risk of cardiovascular disease. Lancet 2, 1288-1289. doi: 10.1016/S0140-6736(81)91524-5.
19. Danesh, J., and Appleby, P. (1999). Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 99, 852-854. doi: 10.1161/01.CIR.99.7.852.
20. Datz, C., Felder, T. K., Niederseer, D., and Aigner, E. (2013). Iron homeostasis in the metabolic syndrome. Eur. J. Clin. Invest. 43, 215-224. doi: 10.1111/eci.12032.
21. Dongiovanni, P., Fracanzani, A. L., Fargion, S., and Valenti, L. (2011). Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J. Hepatol. 55, 920-932. doi: 10.1016/j.jhep.2011.05.008.
22. Dongiovanni, P., Ruscica, M., Rametta, R., Recalcati, S., Steffani, L., Gatti, S., et al. (2013). Dietary iron overload induces visceral adipose tissue insulin resistance. Am. J. Pathol. 182, 2254-2263. doi: 10.1016/j.ajpath.2013.02.019.
23. Dunn, T., Blankenship, D., Beal, N., Allen, R., Schechter, E., Moore, W., et al. (2008). HFE mutations in heart disease. Heart Vessels 23, 348-355. doi: 10.1007/s00380-008-1047-8.
24. Dymock, I. W., Cassar, J., Pyke, D. A., Oakley, W. G., and Williams, R. (1972). Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am. J. Med. 52, 203-210. doi: 10.1016/0002-9343(72)90070-8.
25. Engberink, M. F., Povel, C. M., Durga, J., Swinkels, D. W., De Kort, W. L., Schouten, E. G., et al. (2010). Hemochromatosis (HFE) genotype and atherosclerosis: increased susceptibility to iron-induced vascular damage in C282Y carriers? Atherosclerosis 211, 520-525. doi: 10.1016/j.atherosclerosis.2010.03.018.
26. Fernandez-Cao, J. C., Arija, V., Aranda, N., Bullo, M., Basora, J., Martinez-Gonzalez, M. A., et al. (2013). Heme iron intake and risk of new-onset diabetes in a Mediterranean population at high risk of cardiovascular disease: an observational cohort analysis. BMC Public Health 13:1042. doi: 10.1186/1471-2458-13-1042.
27. Fernandez-Real, J. M., Penarroja, G., Castro, A., Garcia-Bragado, F., Hernandez-Aguado, I., and Ricart, W. (2002). Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 51, 1000-1004. doi: 10.2337/diabetes.51.4.1000.
28. Ferrannini, E. (2000). Insulin resistance, iron, and the liver. Lancet 355, 2181-2182. doi: 10.1016/S0140-6736(00)02397-7.
29. Forouhi, N. G., Harding, A. H., Allison, M., Sandhu, M. S., Welch, A., Luben, R., et al. (2007). Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50, 949-956. doi: 10.1007/s00125-007-0604-5.
30. Forstermann, U. (2008). Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 5, 338-349. doi: 10.1038/ncpcardio1211.
31. Friedrich, N., Milman, N., Volzke, H., Linneberg, A., and Jorgensen, T. (2009). Is serum ferritin within the reference range a risk predictor of cardiovascular disease? A population-based, long-term study comprising 2874 subjects. Br. J. Nutr. 102, 594-600. doi: 10.1017/S000711450922085X.
32. Gabrielsen, J. S., Gao, Y., Simcox, J. A., Huang, J., Thorup, D., Jones, D., et al. (2012). Adipocyte iron regulates adiponectin and insulin sensitivity. J. Clin. Invest. 122, 3529-3540. doi: 10.1172/JCI44421.
33. Gaenzer, H., Marschang, P., Sturm, W., Neumayr, G., Vogel, W., Patsch, J., et al. (2002). Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J. Am. Coll. Cardiol. 40, 2189-2194. doi: 10.1016/S0735-1097(02)02611-6.
34. Ganz, T. (2013). Systemic iron homeostasis. Physiol. Rev. 93, 1721-1741. doi: 10.1152/physrev.00008.2013.
35. Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., et al. (2013). Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, e6-e245. doi: 10.1161/CIR.0b013e318282ab8f.
36. Gonzalez, A. S., Guerrero, D. B., Soto, M. B., Diaz, S. P., Martinez-Olmos, M., and Vidal, O. (2006). Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur. J. Clin. Nutr. 60, 802-809. doi: 10.1038/sj.ejcn.1602384.
37. Gordon, T., Kannel, W. B., Hjortland, M. C., and Mcnamara, P. M. (1978). Menopause and coronary heart disease. The Framingham Study. Ann. Intern. Med. 89, 157-161. doi: 10.7326/0003-4819-89-2-157.
38. Green, A., Basile, R., and Rumberger, J. M. (2006). Transferrin and iron induce insulin resistance of glucose transport in adipocytes. Metabolism 55, 1042-1045. doi: 10.1016/j.metabol.2006.03.015.
39. Greenberg, A. S., and Obin, M. S. (2006). Obesity and the role of adipose tissue in inflammation and metabolism. Am. J. Clin. Nutr. 83, 461S-465S.
40. Gupta, R., Rastogi, S., Nagar, R., Kastia, S., and Kaul, V. (2000). Dietary and serum iron, body iron stores and coronary heart disease. J. Assoc. Physicians India 48, 489-492.
41. Halle, M., Konig, D., Berg, A., Keul, J., and Baumstark, M. W. (1997). Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease. Atherosclerosis 128, 235-240. doi: 10.1016/S0021-9150(96)05994-1.
42. Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., et al. (2011). Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123, 933-944. doi: 10.1161/CIR.0b013e31820a55f5.
43. Heron, M., Hoyert, D. L., Murphy, S. L., Xu, J., Kochanek, K. D., and Tejada-Vera, B. (2009). Deaths: final data for 2006. Natl. Vital. Stat. Rep. 57, 1-134.
44. Houschyar, K. S., Ludtke, R., Dobos, G. J., Kalus, U., Broecker-Preuss, M., Rampp, T., et al. (2012). Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med. 10:54. doi: 10.1186/1741-7015-10-54.
45. Huang, J., Jones, D., Luo, B., Sanderson, M., Soto, J., Abel, E. D., et al. (2011). Iron overload and diabetes risk: a shift from glucose to Fatty Acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis. Diabetes Metab. Res. Rev. 60, 80-87. doi: 10.2337/db10-0593.
46. Inoue, Y., Nakanishi, K., Hiraga, T., Okubo, M., Murase, T., Kosaka, K., et al. (1997). Recovery of pancreatic beta-cell function in hemochromatosis: combined treatment with recombinant human erythropoietin and phlebotomy. Am. J. Med. Sci. 314, 401-402. doi: 10.1097/00000441-199712000-00008.
47. Jacobs, A., Miller, F., Worwood, M., Beamish, M. R., and Wardrop, C. A. (1972). Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. Br. Med. J. 4, 206-208. doi: 10.1136/bmj.4.5834.206.
48. Jacobs, A., and Worwood, M. (1975). Ferritin in serum. Clinical and biochemical implications. N. Engl. J. Med. 292, 951-956. doi: 10.1056/NEJM197505012921805.
49. Jehn, M., Clark, J. M., and Guallar, E. (2004). Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27, 2422-2428. doi: 10.2337/diacare.27.10.2422.
50. Jehn, M. L., Guallar, E., Clark, J. M., Couper, D., Duncan, B. B., Ballantyne, C. M., et al. (2007). A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Epidemiol. 165, 1047-1054. doi: 10.1093/aje/kwk093.
51. Jiang, R., Manson, J. E., Meigs, J. B., Ma, J., Rifai, N., and Hu, F. B. (2004). Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291, 711-717. doi: 10.1001/jama.291.6.711.
52. Kaltwasser, J. P., and Werner, E. (1989). Diagnosis and clinical evaluation of iron overload. Baillieres Clin. Haematol. 2, 363-389. doi: 10.1016/S0950-3536(89)80022-8.
53. Kaluza, J., Wolk, A., and Larsson, S. C. (2013). Heme iron intake and risk of stroke: a prospective study of men. Stroke 44, 334-339. doi: 10.1161/STROKEAHA.112.679662.
54. Kautz, L., Gabayan, V., Wang, X., Wu, J., Onwuzurike, J., Jung, G., et al. (2013). Testing the iron hypothesis in a mouse model of atherosclerosis. Cell Rep. 5, 1436-1442. doi: 10.1016/j.celrep.2013.11.009.
55. Kiechl, S., Willeit, J., Egger, G., Poewe, W., and Oberhollenzer, F. (1997). Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 96, 3300-3307. doi: 10.1161/01.CIR.96.10.3300.
56. Knottnerus, J. A., Swaen, G. M., Slangen, J. J., Volovics, A., and Durinck, J. (1988). Haematologic parameters as risk factors for cardiac infarction, in an occupational health care setting. J. Clin. Epidemiol. 41, 67-74. doi: 10.1016/0895-4356(88)90010-8.
57. Knuiman, M. W., Divitini, M. L., Olynyk, J. K., Cullen, D. J., and Bartholomew, H. C. (2003). Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am. J. Epidemiol. 158, 144-149. doi: 10.1093/aje/kwg121.
58. Lee, C. C., Adler, A. I., Sandhu, M. S., Sharp, S. J., Forouhi, N. G., Erqou, S., et al. (2009). Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 52, 1040-1047. doi: 10.1007/s00125-009-1338-3.
59. Lee, D. H., Folsom, A. R., and Jacobs, D. R. Jr. (2004). Dietary iron intake and Type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia 47, 185-194. doi: 10.1007/s00125-003-1307-1.
60. Li, J., Wang, R., Luo, D., Li, S., and Xiao, C. (2013). Association between serum ferritin levels and risk of the metabolic syndrome in Chinese adults: a population study. PLoS ONE 8:e74168. doi: 10.1371/journal.pone.0074168.
61. Luan de, C., Li, H., Li, S. J., Zhao, Z., Li, X., and Liu, Z. M. (2008). Body iron stores and dietary iron intake in relation to diabetes in adults in North China. Diabetes Care 31, 285-286. doi: 10.2337/dc07-0921.
62. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., et al. (2001). Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes Metab. Res. Rev. 50, 1844-1850.
63. Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., et al. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917-923. doi: 10.1053/jhep.2003.50161.
64. McCord, J. M. (1991). Is iron sufficiency a risk factor in ischemic heart disease? Circulation 83, 1112-1114. doi: 10.1161/01.CIR.83.3.1112.
65. Mendler, M. H., Turlin, B., Moirand, R., Jouanolle, A. M., Sapey, T., Guyader, D., et al. (1999). Insulin resistance-associated hepatic iron overload. Gastroenterology 117, 1155-1163. doi: 10.1016/S0016-5085(99)70401-4.
66. Merkel, P. A., Simonson, D. C., Amiel, S. A., Plewe, G., Sherwin, R. S., Pearson, H. A., et al. (1988). Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N. Engl. J. Med. 318, 809-814. doi: 10.1056/NEJM198803313181303.
67. Montonen, J., Boeing, H., Steffen, A., Lehmann, R., Fritsche, A., Joost, H. G., et al. (2012). Body iron stores and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetologia 55, 2613-2621. doi: 10.1007/s00125-012-2633-y.
68. Nelson, C. W., Wei, E. P., Povlishock, J. T., Kontos, H. A., and Moskowitz, M. A. (1992). Oxygen radicals in cerebral ischemia. Am. J. Physiol. 263, H1356-H1362.
69. Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., et al. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090-2093. doi: 10.1126/science.1104742.
70. Niederau, C., Berger, M., Stremmel, W., Starke, A., Strohmeyer, G., Ebert, R., et al. (1984). Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia 26, 441-444. doi: 10.1007/BF00262217.
71. Pan, A., Sun, Q., Bernstein, A. M., Schulze, M. B., Manson, J. E., Willett, W. C., et al. (2011). Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. Am. J. Clin. Nutr. 94, 1088-1096. doi: 10.3945/ajcn.111.018978.
72. Paraskevaidis, I. A., Iliodromitis, E. K., Vlahakos, D., Tsiapras, D. P., Nikolaidis, A., Marathias, A., et al. (2005). Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. Eur. Heart J. 26, 263-270. doi: 10.1093/eurheartj/ehi028.
73. Powell, L. W., George, D. K., McDonnell, S. M., and Kowdley, K. V. (1998). Diagnosis of hemochromatosis. Ann. Intern. Med. 129, 925-931. doi: 10.7326/0003-4819-129-11_Part_2-199812011-00002.
74. Rajapurkar, M. M., Shah, S. V., Lele, S. S., Hegde, U. N., Lensing, S. Y., Gohel, K., et al. (2012). Association of catalytic iron with cardiovascular disease. Am. J. Cardiol. 109, 438-442. doi: 10.1016/j.amjcard.2011.09.032.
75. Rajpathak, S., Ma, J., Manson, J., Willett, W. C., and Hu, F. B. (2006). Iron intake and the risk of type 2 diabetes in women: a prospective cohort study. Diabetes Care 29, 1370-1376. doi: 10.2337/dc06-0119.
76. Rajpathak, S. N., Crandall, J. P., Wylie-Rosett, J., Kabat, G. C., Rohan, T. E., and Hu, F. B. (2009). The role of iron in type 2 diabetes in humans. Biochim. Biophys. Acta 1790, 671-681. doi: 10.1016/j.bbagen.2008.04.005.
77. Riva, A., Trombini, P., Mariani, R., Salvioni, A., Coletti, S., Bonfadini, S., et al. (2008). Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J. Gastroenterol. 14, 4745-4752. doi: 10.3748/wjg.14.4745.
78. Roest, M., Van Der Schouw, Y. T., De Valk, B., Marx, J. J., Tempelman, M. J., De Groot, P. G., et al. (1999). Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 100, 1268-1273. doi: 10.1161/01.CIR.100.12.1268.
79. Salonen, J. T., Nyyssonen, K., Korpela, H., Tuomilehto, J., Seppanen, R., and Salonen, R. (1992a). High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86, 803-811. doi: 10.1161/01.CIR.86.3.803.
80. Salonen, J. T., Yla-Herttuala, S., Yamamoto, R., Butler, S., Korpela, H., Salonen, R., et al. (1992b). Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339, 883-887. doi: 10.1016/0140-6736(92)90926-T.
81. Salonen, J. T., Tuomainen, T. P., Nyyssonen, K., Lakka, H. M., and Punnonen, K. (1998). Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ 317:727. doi: 10.1136/bmj.317.7160.727.
82. Skikne, B. S., Flowers, C. H., and Cook, J. D. (1990). Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 75, 1870-1876.
83. Song, J. W., and Chung, K. C. (2010). Observational studies: cohort and case-control studies. Plast. Reconstr. Surg. 126, 2234-2242. doi: 10.1097/PRS.0b013e3181f44abc.
84. Steen, D. L., Cannon, C. P., Lele, S. S., Rajapurkar, M. M., Mukhopadhyay, B., Scirica, B. M., et al. (2013). Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clin. Cardiol. 36, 139-145. doi: 10.1002/clc.22089.
85. Sullivan, J. L. (1981). Iron and the sex difference in heart disease risk. Lancet 1, 1293-1294. doi: 10.1016/S0140-6736(81)92463-6.
86. Sullivan, J. L. (1989). The iron paradigm of ischemic heart disease. Am. Heart J. 117, 1177-1188. doi: 10.1016/0002-8703(89)90887-9.
87. Sullivan, J. L. (2007). Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp. Biol. Med. (Maywood) 232, 1014-1020. doi: 10.3181/0703-MR-54.
88. Sullivan, J. L. (2009). Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim. Biophys. Acta 1790, 718-723. doi: 10.1016/j.bbagen.2008.06.005.
89. Sun, L., Franco, O. H., Hu, F. B., Cai, L., Yu, Z., Li, H., et al. (2008a). Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly chinese. J. Clin. Endocrinol. Metab. 93, 4690-4696. doi: 10.1210/jc.2008-1159.
90. Sun, Q., Ma, J., Rifai, N., Franco, O. H., Rexrode, K. M., and Hu, F. B. (2008b). Excessive body iron stores are not associated with risk of coronary heart disease in women. J. Nutr. 138, 2436-2441. doi: 10.3945/jn.108.097766.
91. Sun, L., Zong, G., Pan, A., Ye, X., Li, H., Yu, Z., et al. (2013). Elevated plasma ferritin is associated with increased incidence of type 2 diabetes in middle-aged and elderly Chinese adults. J. Nutr. 143, 1459-1465. doi: 10.3945/jn.113.177808.
92. Sung, K. C., Kang, S. M., Cho, E. J., Park, J. B., Wild, S. H., and Byrne, C. D. (2012). Ferritin is independently associated with the presence of coronary artery calcium in 12,033 men. Arterioscler. Thromb. Vasc. Biol. 32, 2525-2530. doi: 10.1161/ATVBAHA.112.253088.
93. Theurl, I., Theurl, M., Seifert, M., Mair, S., Nairz, M., Rumpold, H., et al. (2008). Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 111, 2392-2399. doi: 10.1182/blood-2007-05-090019.
94. Thomas, C. E., Morehouse, L. A., and Aust, S. D. (1985). Ferritin and superoxide-dependent lipid peroxidation. J. Biol. Chem. 260, 3275-3280.
95. Tiedge, M., Lortz, S., Drinkgern, J., and Lenzen, S. (1997). Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46, 1733-1742. doi: 10.2337/diab.46.11.1733.
96. Tuomainen, T. P., Punnonen, K., Nyyssonen, K., and Salonen, J. T. (1998). Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 97, 1461-1466. doi: 10.1161/01.CIR.97.15.1461.
97. Turoczi, T., Jun, L., Cordis, G., Morris, J. E., Maulik, N., Stevens, R. G., et al. (2003). HFE mutation and dietary iron content interact to increase ischemia/reperfusion injury of the heart in mice. Circ. Res. 92, 1240-1246. doi: 10.1161/01.RES.0000076890.59807.23.
98. Valenti, L., Dongiovanni, P., and Fargion, S. (2012). Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J. Gastroenterol. 18, 3782-3786. doi: 10.3748/wjg.v18.i29.3782.
99. Valenti, L., Dongiovanni, P., Fracanzani, A. L., Santorelli, G., Fatta, E., Bertelli, C., et al. (2003). Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig. Liver Dis. 35, 172-178. doi: 10.1016/S1590-8658(03)00025-2.
100. Valenti, L., Dongiovanni, P., Piperno, A., Fracanzani, A. L., Maggioni, M., Rametta, R., et al. (2006). Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology 44, 857-864. doi: 10.1002/hep.21329.
101. Valenti, L., Fracanzani, A. L., Bugianesi, E., Dongiovanni, P., Galmozzi, E., Vanni, E., et al. (2010). HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 138, 905-912. doi: 10.1053/j.gastro.2009.11.013.
102. Valenti, L., Fracanzani, A. L., Dongiovanni, P., Bugianesi, E., Marchesini, G., Manzini, P., et al. (2007). Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am. J. Gastroenterol. 102, 1251-1258. doi: 10.1111/j.1572-0241.2007.01192.x.
103. Valenti, L., Fracanzani, A. L., Dongiovanni, P., Rovida, S., Rametta, R., Fatta, E., et al. (2014). A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J. Gastroenterol. 20, 3002-3010. doi: 10.3748/wjg.v20.i11.3002.
104. Valenti, L., Swinkels, D. W., Burdick, L., Dongiovanni, P., Tjalsma, H., Motta, B. M., et al. (2011). Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 21, 568-575. doi: 10.1016/j.numecd.2010.01.003.
105. van der, A. D., Grobbee, D. E., Roest, M., Marx, J. J., Voorbij, H. A., and Van Der Schouw, Y. T. (2005). Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke 36, 1637-1641. doi: 10.1161/01.STR.0000173172.82880.72.
106. van der, A. D., Peeters, P. H., Grobbee, D. E., Roest, M., Marx, J. J., Voorbij, H. M., et al. (2006). HFE mutations and risk of coronary heart disease in middle-aged women. Eur. J. Clin. Invest. 36, 682-690. doi: 10.1111/j.1365-2362.2006.01711.x.
107. von Bonsdorff, L., Lindeberg, E., Sahlstedt, L., Lehto, J., and Parkkinen, J. (2002). Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologic malignancies. Clin. Chem. 48, 307-314.
108. Wang, W., Knovich, M. A., Coffman, L. G., Torti, F. M., and Torti, S. V. (2010). Serum ferritin: past, present and future. Biochim. Biophys. Acta 1800, 760-769. doi: 10.1016/j.bbagen.2010.03.011.
109. Williams, R. E., Zweier, J. L., and Flaherty, J. T. (1991). Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts. Circulation 83, 1006-1014. doi: 10.1161/01.CIR.83.3.1006.
110. Witte, D. L., Crosby, W. H., Edwards, C. Q., Fairbanks, V. F., and Mitros, F. A. (1996). Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin. Chim. Acta 245, 139-200. doi: 10.1016/0009-8981(95)06212-2.
111. Wlazlo, N., Van Greevenbroek, M. M., Ferreira, I., Jansen, E. H., Feskens, E. J., Van Der Kallen, C. J., et al. (2013). Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 36, 309-315. doi: 10.2337/dc12-0505.
112. Wolff, B., Volzke, H., Ludemann, J., Robinson, D., Vogelgesang, D., Staudt, A., et al. (2004). Association between high serum ferritin levels and carotid atherosclerosis in the study of health in Pomerania (SHIP). Stroke 35, 453-457. doi: 10.1161/01.STR.0000114875.31599.1C.
113. Wolff, S. P. (1993). Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br. Med. Bull. 49, 642-652.
114. Wrede, C. E., Buettner, R., Bollheimer, L. C., Scholmerich, J., Palitzsch, K. D., and Hellerbrand, C. (2006). Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur. J. Endocrinol. 154, 333-340. doi: 10.1530/eje.1.02083.
115. Zacharski, L. R., Shamayeva, G., and Chow, B. K. (2011). Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am. Heart J. 162, 949.e1-957.e1. doi: 10.1016/j.ahj.2011.08.013.
116. Zhang, W., Iso, H., Ohira, T., Date, O. C., Tanabe, N., Kikuchi, S., et al. (2012). Associations of dietary iron intake with mortality from cardiovascular disease: the JACC study. J. Epidemiol. 22, 484-493. doi: 10.2188/jea.JE20120006.
117. Zhao, Z., Li, S., Liu, G., Yan, F., Ma, X., Huang, Z., et al. (2012). Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 7:e41641. doi: 10.1371/journal.pone.0041641.